{
    "id": "dbpedia_1729_1",
    "rank": 72,
    "data": {
        "url": "https://link.springer.com/chapter/10.1007/978-3-319-56694-8_5",
        "read_more_link": "",
        "language": "en",
        "title": "Syphilis",
        "top_image": "https://static-content.springer.com/cover/book/978-3-319-56694-8.jpg",
        "meta_img": "https://static-content.springer.com/cover/book/978-3-319-56694-8.jpg",
        "images": [
            "https://link.springer.com/oscar-static/images/darwin/header/img/logo-springerlink-39ee2a28d8.svg",
            "https://media.springernature.com/w72/springer-static/cover-hires/book/978-3-319-56694-8?as=webp",
            "https://media.springernature.com/w92h120/springer-static/cover-hires/book/978-3-031-15130-9?as=webp",
            "https://media.springernature.com/w92h120/springer-static/cover-hires/book/978-3-662-63709-8?as=webp",
            "https://media.springernature.com/w92h120/springer-static/cover-hires/book/978-3-540-75387-2?as=webp",
            "https://link.springer.com/oscar-static/images/logo-springernature-white-19dd4ba190.svg"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [
            "James Lewis",
            "Arlene C. Seña",
            "Arlene C"
        ],
        "publish_date": "2017-08-11T00:00:00",
        "summary": "",
        "meta_description": "Syphilis is a sexually transmitted infection (STI) caused by Treponema pallidum subsp. pallidum. The incidence of syphilis was greatly reduced after the introduction of penicillin in 1943. However, after reaching an all-time nadir in the late 1990s, syphilis...",
        "meta_lang": "en",
        "meta_favicon": "/oscar-static/img/favicons/darwin/apple-touch-icon-92e819bf8a.png",
        "meta_site_name": "SpringerLink",
        "canonical_link": "https://link.springer.com/chapter/10.1007/978-3-319-56694-8_5",
        "text": "Singh AE, Romanowski B. Syphilis: review with emphasis on clinical, epidemiologic, and some biologic features. Clin Microbiol Rev. 1999;12(2):187–209.\n\nAdegoke AO, Akanni O, Dirisu J. Risk of transfusion-transmitted syphilis in a tertiary hospital in Nigeria. N Am J Med Sci. 2011;3(2):78–81.\n\nPerkins HA, Busch MP. Transfusion-associated infections: 50 years of relentless challenges and remarkable progress. Transfusion. 2010;50(10):2080–99.\n\nTariciotti L, Das I, Dori L, Perera MT, Bramhall SR. Asymptomatic transmission of Treponema pallidum (syphilis) through deceased donor liver transplantation. Transpl Infect Dis. 2012;14(3):321–5.\n\nFenton KA, Breban R, Vardavas R, Okano JT, Martin T, Aral S, et al. Infectious syphilis in high-income settings in the 21st century. Lancet Infect Dis. 2008;8(4):244–53.\n\nLafond RE, Lukehart SA. Biological basis for syphilis. Clin Microbiol Rev. 2006;19(1):29–49.\n\nGayet-Ageron A, Ninet B, Toutous-Trellu L, Lautenschlager S, Furrer H, Piguet V, et al. Assessment of a real-time PCR test to diagnose syphilis from diverse biological samples. Sexually Transm Infect. 2009;85(4):264–9.\n\nZetola NM, Engelman J, Jensen TP, Klausner JD. Syphilis in the United States: an update for clinicians with an emphasis on HIV coinfection. Mayo Clin Proc. 2007;82(9):1091–102.\n\nCenters for Disease Control and Prevention. Sexually transmitted disease surveillance 2013. Atlanta: U.S. Department of Health and Human Services; 2014.\n\nShockman S, Buescher LS, Stone SP. Syphilis in the United States. Clin Dermatol. 2014;32(2):213–8.\n\nThe L. Syphilis on the rise in the USA. The Lancet. 2011;378(9791):542.\n\nAral SO, O’Leary A, Baker C. Sexually transmitted infections and HIV in the southern United States: an overview. Sex Transm Dis. 2006;33(7 Suppl):S1–5.\n\nSu JR, Beltrami JF, Zaidi AA, Weinstock HS. Primary and secondary syphilis among black and Hispanic men who have sex with men: case report data from 27 States. Ann Intern Med. 2011;155(3):145–51.\n\nCameron CE, Lukehart SA. Current status of syphilis vaccine development: need, challenges, prospects. Vaccine. 2014;32(14):1602–9.\n\nJarzebowski W, Caumes E, Dupin N, Farhi D, Lascaux AS, Piketty C, et al. Effect of early syphilis infection on plasma viral load and CD4 cell count in human immunodeficiency virus-infected men: results from the FHDH-ANRS CO4 cohort. Arch Intern Med. 2012;172(16):1237–43.\n\nGalvin SR, Cohen MS. The role of sexually transmitted diseases in HIV transmission. Nat Rev Microbiol. 2004;2(1):33–42.\n\nHo EL, Lukehart SA. Syphilis: using modern approaches to understand an old disease. J Clin Invest. 2011;121(12):4584–92.\n\nSellati TJ, Wilkinson DA, Sheffield JS, Koup RA, Radolf JD, Norgard MV. Virulent Treponema pallidum, lipoprotein, and synthetic lipopeptides induce CCR5 on human monocytes and enhance their susceptibility to infection by human immunodeficiency virus type 1. J Infect Dis. 2000;181(1):283–93.\n\nGalvin SR, Cohen MS. The role of sexually transmitted diseases in HIV transmission. Nat Rev Microbiol. 2004;2(1):33–42.\n\nTheus SA, Harrich DA, Gaynor R, Radolf JD, Norgard MV. Treponema pallidum, lipoproteins, and synthetic lipoprotein analogues induce human immunodeficiency virus type 1 gene expression in monocytes via NF-κB activation. J Infect Dis. 1998;177(4):941–50.\n\nLibois A, De Wit S, Poll B, Garcia F, Florence E, Del Rio A, et al. HIV and syphilis: when to perform a lumbar puncture. Sex Transm Dis. 2007;34(3):141–4.\n\nTucker JD, Cohen MS. China’s syphilis epidemic: epidemiology, proximate determinants of spread, and control responses. Current Opinion in Infectious Diseases. 2011;24(1):50–5.\n\nWHO. Global incidence and prevalence of selected curable sexually transmitted infections. 2008. Available at: http://apps.who.int/iris/bitstream/10665/75181/1/9789241503839_eng?ua=1. Accessed 24 Sept 2015.\n\nPurcell DW, Johnson CH, Lansky A, Prejean J, Stein R, Denning P, et al. Estimating the population size of men who have sex with men in the United States to obtain HIV and syphilis rates. Open AIDS J. 2012;6:98–107.\n\nPeterman TA, Heffelfinger JD, Swint EB, Groseclose SL. The changing epidemiology of syphilis. Sex Transm Dis. 2005;32(supplement):S4–10.\n\nZetola NM, Klausner JD. Syphilis and HIV infection: an update. Clin Infect Dis. 2007;44(9):1222–8.\n\nPathela P, Braunstein SL, Schillinger JA, Shepard C, Sweeney M, Blank S. Men who have sex with men have a 140-fold higher risk for newly diagnosed HIV and syphilis compared with heterosexual men in New York City. J Acquir Immune Defic Syndr. 2011;58(4):408–16.\n\nKalichman SC, Pellowski J, Turner C. Prevalence of sexually transmitted co-infections in people living with HIV/AIDS: systematic review with implications for using HIV treatments for prevention. Sexually Transm Infect. 2011;87(3):183–90.\n\nPathela P, Braunstein SL, Blank S, Shepard C, Schillinger JA. The high risk of an HIV diagnosis following a diagnosis of syphilis: a population-level analysis of New York City men. Clin Infect Dis. 2015;61(2):281–7.\n\nGrov C, Rendina HJ, Moody RL, Ventuneac A, Parsons JT. HIV serosorting, status disclosure, and strategic positioning among highly sexually active gay and bisexual men. AIDS Patient Care STDS. 2015;29(10):559–68.\n\nBirkett M, Kuhns LM, Latkin C, Muth S, Mustanski B. The sexual networks of racially diverse young men who have sex with men. Arch Sex Behav. 2015;44(7):1787–97.\n\nPeters JJ, Peers JH, Olansky S, Cutler JC, Gleeson GA. Untreated syphilis in the male Negro; pathologic findings in syphilitic and nonsyphilitic patients. J Chronic Dis. 1955;1(2):127–48.\n\nTucker JD, Shah S, Jarell AD, Tsai KY, Zembowicz A, Kroshinsky D. Lues maligna in early HIV infection case report and review of the literature. Sex Transm Dis. 2009;36(8):512–4.\n\nBork JT, Macharia T, Choi J, Gilliam BL, Buchwald UK. Syphilitic hepatitis treated with doxycycline in an HIV-infected patient and review of the literature. Sex Transm Dis. 2014;41(8):507–10.\n\nGhanem KG. REVIEW: neurosyphilis: a historical perspective and review. CNS Neurosci Ther. 2010;16(5):e157–68.\n\nDavis JL. Ocular syphilis. Curr Opin Ophthalmol. 2014;25(6):513–8.\n\nTucker JD, Li JZ, Robbins GK, Davis BT, Lobo AM, Kunkel J, et al. Ocular syphilis among HIV-infected patients: a systematic analysis of the literature. Sexually transmitted infections. 2011;87(1):4–8.\n\nMarra CM, Deutsch R, Collier AC, Morgello S, Letendre S, Clifford D, et al. Neurocognitive impairment in HIV-infected individuals with previous syphilis. Int J STD AIDS. 2013;24(5):351–5.\n\nGhanem KG, Erbelding EJ, Wiener ZS, Rompalo AM. Serological response to syphilis treatment in HIV-positive and HIV-negative patients attending sexually transmitted diseases clinics. Sexually Transm Infect. 2007;83(2):97–101.\n\nGhanem KG. Evaluation and management of syphilis in the HIV-infected patient. Curr Infect Dis Rep. 2010;12(2):140–6.\n\nJackman JD Jr, Radolf JD. Cardiovascular syphilis. Am J Med. 1989;87(4):425–33.\n\nCox DL. Culture of Treponema pallidum. Methods Enzymol. 1994;236:390–405.\n\nTipple C, Taylor GP. Syphilis testing, typing, and treatment follow-up: a new era for an old disease. Curr Opin Infect Dis. 2015;28(1):53–60.\n\nPeng RR, Wang AL, Li J, Tucker JD, Yin YP, Chen XS. Molecular typing of Treponema pallidum: a systematic review and meta-analysis. PLoS Negl Trop Dis. 2011;5(11):e1273.\n\nSena AC, Pillay A, Cox DL, Radolf JD. Treponema and Brachyspira, human host-associated spirochetes. In: Jorgensen JH, Pfaller MA, Carroll KC, et al. editors. Manual of clinical microbiology. 11th ed. Washington, DC: ASM Press; 2011. p. 1055–81.\n\nWorkowski KA, Bolan GA, Centers for Disease C, Prevention. Sexually transmitted diseases treatment guidelines. MMWR Recomm Rep. 2015;64(RR-03):1–137.\n\nJurado RL, Campbell J, Martin PD. Prozone phenomenon in secondary syphilis. Has its time arrived? Arch Intern Med. 1993;153(21):2496–8.\n\nPost JJ, Khor C, Furner V, Smith DE, Whybin LR, Robertson PW. Case report and evaluation of the frequency of the prozone phenomenon in syphilis serology—an infrequent but important laboratory phenomenon. Sex Health. 2012;9(5):488–90.\n\nYin YP, Chen XS, Wei WH, Gong KL, Cao WL, Yong G, et al. A dual point-of-care test shows good performance in simultaneously detecting nontreponemal and treponemal antibodies in patients with syphilis: a multisite evaluation study in China. Clin Infect Dis. 2013;56(5):659–65.\n\nCenters for Disease C, Prevention. Discordant results from reverse sequence syphilis screening—five laboratories, United States, 2006–2010. MMWR Morb Mortal Wkly Rep. 2011;60(5):133–7.\n\nZhang W, Yen-Lieberman B, Means C, Kreller R, Waletzky J, Daly TM. The impact of analytical sensitivity on screening algorithms for syphilis. Clin Chem. 2012;58(6):1065–6.\n\nMorshed MG, Singh AE. Recent trends in the serologic diagnosis of syphilis. Clin Vaccine Immunol. 2015;22(2):137–47.\n\nTong ML, Lin LR, Liu LL, Zhang HL, Huang SJ, Chen YY, et al. Analysis of 3 algorithms for syphilis serodiagnosis and implications for clinical management. Clin Infect Dis. 2014;58(8):1116–24.\n\nOwusu-Edusei K Jr, Koski KA, Ballard RC. The tale of two serologic tests to screen for syphilis–treponemal and nontreponemal: does the order matter? Sex Transm Dis. 2011;38(5):448–56.\n\nOwusu-Edusei K Jr, Peterman TA, Ballard RC. Serologic testing for syphilis in the United States: a cost-effectiveness analysis of two screening algorithms. Sex Transm Dis. 2011;38(1):1–7.\n\nMarra CM, Tantalo LC, Maxwell CL, Ho EL, Sahi SK, Jones T. The rapid plasma reagin test cannot replace the venereal disease research laboratory test for neurosyphilis diagnosis. Sex Transm Dis. 2012;39(6):453–7.\n\nMarra CM, Tantalo LC, Sahi SK, Maxwell CL, Lukehart SA. CXCL13 as a cerebrospinal fluid marker for neurosyphilis in HIV-infected patients with syphilis. Sex Transm Dis. 2010;37(5):283–7.\n\n“Guide for HIV/AIDS clinical care” pdf obtained from http://hab.hrsa.gov/deliverhivaidscare/2014guide.pdf. 28 Oct 2015.\n\nClement ME, Okeke NL, Hicks CB. Treatment of syphilis: a systematic review. JAMA. 2014;312(18):1905–17.\n\nGhanem KG. Evaluation and management of syphilis in the HIV-infected patient. Curr Infect Dis Rep. 2010;12(2):140–6.\n\nGhanem KG, Workowski KA. Management of adult syphilis. Clin Infect Dis. 2011;53(Suppl 3):S110–28.\n\nLawrence D, Cresswell F, Whetham J, Fisher M. Syphilis treatment in the presence of HIV: the debate goes on. Curr Opin Infect Dis. 2015;28(1):44–52.\n\nTuddenham S, Ghanem KG. Editorial commentary: the optimal dose of penicillin when treating syphilis in HIV-infected persons: enough, already? Clin Infect Dis. 2015;60(4):661–3.\n\nGhanem KG, Erbelding EJ, Cheng WW, Rompalo AM. Doxycycline compared with benzathine penicillin for the treatment of early syphilis. Clin Infect Dis. 2006;42(6):e45–9.\n\nGhanem KG. Evaluation and management of syphilis in the HIV-infected patient. Curr Infect Dis Rep. 2010;12(2):140–6.\n\nGhanem KG, Workowski KA. Management of adult syphilis. Clin Infect Dis. 2011;53(Suppl 3):S110–28.\n\nChen CY, Chi KH, Pillay A, Nachamkin E, Su JR, Ballard RC. Detection of the A2058G and A2059G 23S rRNA gene point mutations associated with azithromycin resistance in Treponema pallidum by use of a TaqMan real-time multiplex PCR assay. J Clin Microbiol. 2013;51(3):908–13.\n\nLewis DA, Lukehart SA. Antimicrobial resistance in Neisseria gonorrhoeae and Treponema pallidum: evolution, therapeutic challenges and the need to strengthen global surveillance. Sex Trans Infect. 2011;87(Suppl 2):ii39–43.\n\nStamm LV. Syphilis: antibiotic treatment and resistance. Epidemiol Infect. 2015;143(8):1567–74.\n\nLukehart SA, Godornes C, Molini BJ, Sonnett P, Hopkins S, Mulcahy F, et al. Macrolide resistance in Treponema pallidum in the United States and Ireland. N Engl J Med. 2004;351(2):154–8.\n\nYang CJ, Lee NY, Lin YH, Lee HC, Ko WC, Liao CH, et al. Jarisch–Herxheimer reaction after penicillin therapy among patients with syphilis in the era of the HIV infection epidemic: incidence and risk factors. Clin Infect Dis. 2010;51(8):976–9.\n\nSena AC, Zhang XH, Li T, Zheng HP, Yang B, Yang LG, et al. A systematic review of syphilis serological treatment outcomes in HIV-infected and HIV-uninfected persons: rethinking the significance of serological non-responsiveness and the serofast state after therapy. BMC Infect Dis. 2015;15:479."
    }
}